Canada: Food, Drugs, Healthcare, Life Sciences

The Patented Medicine Prices Review Board (PMPRB) is a Canadian federal agency that regulates the prices of patented medicines in Canada.

On June 30, 2025, the PMPRB published final non-binding guidelines (Guidelines) titled Guidelines for PMPRB Staff: Administrative Process for Excessive Price Hearing Recommendation.

Trademarks are important assets for any business. When it comes to trademark enforcement, options abound, which can sometimes be disorienting for the uninitiated.

The Patented Medicine Prices Review Board (PMPRB) is a Canadian federal agency that regulates the prices of patented medicines in Canada.

On June 30, 2025, the PMPRB published final non-binding guidelines (Guidelines) titled Guidelines for PMPRB Staff: Administrative Process for Excessive Price Hearing Recommendation.

On June 30, 2025, the Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff, which will come into force on January 1, 2026.

The Patented Medicine Prices Review Board (PMPRB) is a Canadian federal agency that regulates the prices of patented medicines in Canada.

On June 30, 2025, the PMPRB published final non-binding guidelines (Guidelines) titled Guidelines for PMPRB Staff: Administrative Process for Excessive Price Hearing Recommendation.

On July 2, 2025, the Ontario government issued a province-wide call for applications to consider the issuance of new licences for Integrated Community Health Services Centres...

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.